Plural Chalcogens Bonded Directly To Ring Carbons Of The Six-membered Hetero Ring Patents (Class 546/296)
-
Publication number: 20110213001Abstract: The object of the present invention is to provide a pharmaceutical composition that inhibits expression of iNOS and COX-2 without inhibiting NF-?B. The pharmaceutical composition that inhibits expression of iNOS and COX-2 without inhibiting NF-?B contains DTCM glutarimide of the Formula (I) as an effective ingredient, thereby being able to inhibit nitric oxide (NO) production and prostaglandin production.Type: ApplicationFiled: June 25, 2009Publication date: September 1, 2011Applicant: KEIO UNIVERSITYInventors: Kazuo Umezawa, Yuichi Ishikawa, Shigeru Nishiyama, Miyuki Tachibana, Ayumi Kaneda
-
Publication number: 20110195993Abstract: The present invention relates to novel PPAR agonist compounds as well as pharmaceutical compositions containing them. The compounds according to the invention are of quite particular therapeutic interest, notably for treating diabetes and/or dyslipidemias, as well as for preventing cardiovascular pathologies.Type: ApplicationFiled: May 26, 2009Publication date: August 11, 2011Inventors: Christophe Masson, Karine Caumont-Bertrand
-
Patent number: 7989478Abstract: The present invention relates to a cinnamoyl compound represented by the formula (I):Type: GrantFiled: September 16, 2004Date of Patent: August 2, 2011Assignee: Sumitomo Chemical Company, LimitedInventors: Yoshitaka Tomigahara, Kiyoshi Higashi, Junya Takahashi, Chizuko Takahashi
-
Publication number: 20110183998Abstract: Heterocyclic derivatives, processes for their preparation, medicaments comprising these compounds, and the use thereof. The invention relates to compounds of the formula I in which the radicals R1, R2, R3, R4, W, A, B, D, E, G, L, M, R, T and Y have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example for the treatment of the metabolic syndrome, insulin resistance, obesity and diabetes.Type: ApplicationFiled: July 7, 2009Publication date: July 28, 2011Applicant: SANOFI-AVENTISInventors: Gerhard Zoller, Dieter Schmoll, Marco Mueller, Guido Haschke, Ingo Focken
-
Publication number: 20110184029Abstract: The present invention relates to 2-pyridone derivatives of Formula I or IV as herein described, compositions containing such compounds, synthetic processes for making such compounds, and therapeutic methods that include the administration of such compounds.Type: ApplicationFiled: July 13, 2009Publication date: July 28, 2011Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Choung U. Kim, Michael L. Mitchell, Jong Chan Son
-
Publication number: 20110183940Abstract: The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the delivery of compounds for the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.Type: ApplicationFiled: July 23, 2009Publication date: July 28, 2011Inventors: Brian Alvin Johns, Jason Gordon Weatherhead, Toshikazu Hakogi, Yasunori Aoyama
-
Patent number: 7973060Abstract: A compound which is effective for inhibiting Fab I, and a method for treating a bacterial infection.Type: GrantFiled: October 11, 2006Date of Patent: July 5, 2011Assignee: CrystalGenomics, Inc.Inventors: Cheol Min Kim, Dong Gyu Shin, Seonggu Ro, Joong Myung Cho, Young Lan Hyun
-
Publication number: 20110144167Abstract: The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.Type: ApplicationFiled: August 21, 2009Publication date: June 16, 2011Applicant: SMITHKLINE BEECHAM CORPORATIONInventor: Rosanna Tedesco
-
Publication number: 20110137041Abstract: The invention provides novel intermediates of atovaquone and use thereof for the preparation of atovaquoneType: ApplicationFiled: June 30, 2008Publication date: June 9, 2011Applicant: CHEMAGIS LTD.Inventors: Fuqiang Zhu, He Qiao, Michel Bekhazi
-
Patent number: 7951822Abstract: The object is to provide a novel LXR? agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. The solving means is a 1,3-dihydroisobenzofuran derivative represented by the following general formula (1) or salt thereof, or their solvate.Type: GrantFiled: March 30, 2009Date of Patent: May 31, 2011Assignee: Kowa Company, Ltd.Inventors: Ayumu Okuda, Takayuki Matsuda, Toru Miura, Koichi Yamazaki, Yuki Yamaguchi, Minoru Koura, Sayaka Kurobuchi, Yuichiro Watanabe, Kimiyuki Shibuya
-
Publication number: 20110118300Abstract: The present invention provides, inter alia, dihydropyridone compounds and compositions, including analogs of a vesicular monoamine transporter type 2 (VMAT2) antagonist. The present invention also provides methods of using such compounds/analogs for modulating glucose levels, and/or preventing, treating, or ameliorating the effects of diabetes and hyper-glycemia.Type: ApplicationFiled: April 10, 2009Publication date: May 19, 2011Inventors: Paul Harris, Antonella Maffei, Yuli Xie, Donald Landry
-
Publication number: 20110108755Abstract: Disclosed are an oligomer and a phthalonitrile monomer having the formulas: M is a metal or H. The value n is an integer greater than or equal to 1 for the oligomer and greater than or equal to 0 for the phthalonitrile monomer. Ar1 and Ar2 are independently selected aromatic- or heterocyclic-containing groups. Ar1, Ar2, or both are heteroaromatic or heterocyclic groups containing a nitrogen, sulfur, or oxygen heteroatom. Also disclosed are thermosets and pyrolyzed materials made from the phthalonitrile monomer.Type: ApplicationFiled: November 12, 2009Publication date: May 12, 2011Applicant: The Government of the United States Of America, as represented by the Secretary of the NavyInventors: Matthew Laskoski, Teddy M Keller
-
Patent number: 7919509Abstract: To provide a novel LXR? agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A 2-oxochromene derivative represented by the following general formula (1) or salt thereof, or their solvate.Type: GrantFiled: February 27, 2009Date of Patent: April 5, 2011Assignee: Kowa Company, Ltd.Inventors: Ayumu Okuda, Takayuki Matsuda, Toru Miura, Hidefumi Ozawa, Ayako Tosaka, Koichi Yamazaki, Yuki Yamaguchi, Sayaka Kurobuchi, Yuichiro Watanabe, Kimiyuki Shibuya
-
Patent number: 7902383Abstract: A method of the invention industrially produces heterocyclic mercapto compounds useful as raw materials or intermediates in the synthesis of medicaments or pesticides, or as permanent wave agent, with a high yield and high productivity using easily available starting materials. A heterocyclic mercapto compound represented by Formula (1) (wherein X represents any structure of —O—, —S—, —NH—, and —NR1—; R1 represents any of an alkyl group, alkoxy group and alkoxyalkyl group each having 1 to 6 carbon atoms; Y represents an oxygen atom, a sulfur atom or —NR2—; R2 represents a hydrogen atom or alkyl group having 1 to 6 carbon atoms; and Z1 represents a divalent organic residue having at least one mercapto group) is produced by reacting a metal sulfide or a metal hydrosulfide with a compound represented by Formula (2) (wherein X and Y are as defined in Formula (1); and Z2 represents a divalent organic residue having at least one halogen group) in the presence of a solvent at a pH of 7.0 to 11.0.Type: GrantFiled: May 28, 2007Date of Patent: March 8, 2011Assignee: Showa Denko K.K.Inventors: Shinichi Yorozuya, Hidemasa Aoki
-
Patent number: 7897624Abstract: This invention concerns N-(ortho phenylamino dihydropyridyl)sulfonamides and N-(ortho phenylamino dihydropyridyl), N?-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases.Type: GrantFiled: April 18, 2007Date of Patent: March 1, 2011Assignee: Ardea BiosciencesInventors: Shunqi Yan, Jean-Michel Vernier, Zhi Hong, Suetying Chow, Yung-hyo Koh
-
Patent number: 7868026Abstract: The present invention provides compounds of formula (I), or pharmaceutically acceptable salts or solvates thereof, methods for their preparation, methods for their use, and pharmaceutical formulations comprising them.Type: GrantFiled: January 9, 2007Date of Patent: January 11, 2011Assignee: Pfizer Inc.Inventors: Mitchell David Nambu, Leena Bharat Kumar Patel, Brian Douglas Patterson, Sylvie Kim Sakata, John Howard Tatlock
-
Publication number: 20100324001Abstract: Methods of inhibiting the cytokine or biological activity of Macrophage Migration Inhibitory Factor (MIF) comprising contacting MIF with a compound of formula (I) are provided. The invention also relates to methods of treating diseases or conditions where MIF cytokine or biological activity is implicated comprising administration of compounds of formula (I), either alone or as a part of combination therapy. Novel compounds of formula (I) are also provided for.Type: ApplicationFiled: June 30, 2010Publication date: December 23, 2010Applicant: Cortical Pty LTDInventors: Eric Francis Morand, Magdy Naguib Iskander, Colin Edward Skene
-
Patent number: 7850955Abstract: Gelling agents which contain a specific N-acylamino acid monoamide monoalkyl ester have a melting temperature of about 100° C., are capable of solidifying a wide variety of oily base materials including silicones, and do not cause “sweating” while retaining a practical level of gel strength. When applied to skin, the resulting gels have a good feeling, good spreadability, and good fittability to skin.Type: GrantFiled: July 3, 2008Date of Patent: December 14, 2010Assignee: Ajinomoto Co., Inc.Inventors: Keitaro Saito, Takanori Sugimoto, Tatsuya Hattori
-
Publication number: 20100310460Abstract: The invention relates to compositions and methods of treatment using an iron chelator, an antioxidant, estrogen, and/or combinations thereof, optionally, linked to a nanoparticle, to treat a subject in need thereof. The compositions and methods may be used to restore or protect the normal functions of osteoblast and osteoclast by depleting iron and inhibiting oxidative damage. The compositions and methods may also be used to increase the bone formation rate in a subject.Type: ApplicationFiled: May 28, 2010Publication date: December 9, 2010Inventors: Gang Liu, Ping Men
-
Publication number: 20100305097Abstract: Compounds of Formula (I) are effective in the treatment of a microbial infection.Type: ApplicationFiled: July 28, 2010Publication date: December 2, 2010Inventors: Namal Chithranga Warshakoon, Rodney Dean Bush
-
Patent number: 7820677Abstract: Stable acid addition salts of certain 2,3-disubstituted pyrazine compounds that are selective for the 5-HT2c receptor and therapeutically active in the central nervous system are described.Type: GrantFiled: February 22, 2006Date of Patent: October 26, 2010Inventors: Tom Fleck, Bruce Fleck, legal representative, Magnus Cernerud, Helena Lundström, Claes Löfström, Margit Pelcman, Alexander Paptchikhine, Emma Andersson, Alf Nygren
-
Patent number: 7820820Abstract: A method of preparing azaindole compounds for antiviral use having the formulaType: GrantFiled: August 24, 2009Date of Patent: October 26, 2010Assignee: Bristol-Myers Squibb CompanyInventors: Wansheng Liu, Sunil S. Patel, Nicolas Cuniere, Yvonne Lear, Prashant P. Deshpande, Jeffrey N. Simon, Chiajen Lai, Annie J. Pullockaran, Nachimuthu Soundararajan, Jeffrey T. Bien
-
Patent number: 7812038Abstract: A method for the inhibition of the binding of ?4?1 integrin to its receptors, for example VCAM-1 (vascular cell adhesion molecule-1) and fibronectin; compounds that inhibit this binding; pharmaceutically active compositions comprising such compounds; and to the use of such compounds either a above, or in formulations for the control or prevention of diseases states in which ?4?1 is involved.Type: GrantFiled: June 14, 2005Date of Patent: October 12, 2010Assignee: Encysive Pharmaceuticals, Inc.Inventors: Ronald J. Biediger, Qi Chen, E. Radford Decker, George W. Holland, Jamal M. Kassir, Wen Li, Robert V. Market, Ian L. Scott, Chengde Wu, Jian Li
-
Patent number: 7811595Abstract: The present disclosure relates to HIF-1? prolyl hydroxylase inhibitors, compositions which comprise the HIF-1? prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.Type: GrantFiled: June 26, 2007Date of Patent: October 12, 2010Assignee: Warner Chilcott Company, LLCInventors: Richard Masaru Kawamoto, Shengde Wu, Namal C. Warshakoon, Artem G. Evdokimov, Kenneth D. Greis, Angelique Sun Boyer
-
Publication number: 20100193774Abstract: The invention relates to quinoid compounds and their use in semiconductive matrix materials, electronic and optoelectronic structural elements.Type: ApplicationFiled: July 2, 2008Publication date: August 5, 2010Applicant: NOVALED AGInventors: Olaf Zeika, Ina Faltin, Andrea Lux, Steffen Willmann
-
Publication number: 20100179137Abstract: [Solving Means] The present inventors have conducted extensive studies on an EP4 receptor agonist, and as a result, found that a novel pyridone compound characterized in that the 1-position in the pyridone ring is substituted with a group having an acidic group such as a carboxyl group and the 6-position is bonded with an aromatic ring group via lower alkyl, lower alkylene, ether, or thioether, has an excellent EP4 receptor agonistic action, thereby completing the present invention. Since the compound of the present invention has an excellent EP4 receptor agonistic action and a blood flow increasing action in the hindlimb of a rat, it is useful as a pharmaceutical, in particular, an agent for treating peripheral arterial occlusive disease.Type: ApplicationFiled: June 6, 2008Publication date: July 15, 2010Inventors: Takashi Kamikubo, Fukushi Hirayama, Masanori Miura, Yuriko Komiya, Takao Okuda, Keisuke Maki
-
Publication number: 20100173951Abstract: The invention relates to the novel chemical compounds of the formula (I): (I) in free or salt form, its use in the treatment of NET and/or SERT mediated conditions, e.g., depression, vasomotor symptoms, e.g., hot flashes and other diseases or conditions mediated by NET and/or SERT.Type: ApplicationFiled: June 4, 2008Publication date: July 8, 2010Inventors: Lawrence Wennogle, Peng Li, Jun Zhao
-
Publication number: 20100168426Abstract: The present application relates to a new process for the asymmetric production of 3-(pyridin-4-yl)-3-hydroxy-pentanoic acid derivatives, which are useful intermediates in the manufacture of compounds that are known to show antiproliferative activity.Type: ApplicationFiled: March 8, 2010Publication date: July 1, 2010Applicant: Ipsen/S.C.R.A.S. (Andre Bourgouin)Inventors: Christian Diolez, Eric Manginot, Rene Peters, Alain Rolland, Marc Veyrat
-
Publication number: 20100168175Abstract: The present invention relates to processes for preparing certain 2-pyridones and 2-pyridinols, to novel compounds of these two types and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection, in the medicinal field and in the protection of materials.Type: ApplicationFiled: December 10, 2009Publication date: July 1, 2010Applicant: BAYER CROPSCIENCE AGInventors: Isabelle ADELT, Robert VELTEN, Welf Burkhard WIESE, Ulrike WACHENDORFF-NEUMANN, Karl-Heinz KUCK, Peter DAHMEN, Arnd VOERSTE, Ronald EBBERT, Franz von NUSSBAUM
-
Publication number: 20100137376Abstract: Disclosed is a plant disease control agent containing an amide compound represented by formula (1) below which has an excellent plant disease controlling effect as an active ingredient. (In the formula, X1, X2, Z1 and E1 are as defined in the description.Type: ApplicationFiled: July 11, 2008Publication date: June 3, 2010Inventors: Takashi Komori, Mayumi Kubota, Yuichi Matsuzaki
-
Patent number: 7714002Abstract: The present invention provides novel urea mimics and analogues of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, W, and R6 are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.Type: GrantFiled: June 26, 2006Date of Patent: May 11, 2010Assignee: Bristol-Myers Squibb CompanyInventor: James C. Sutton
-
Publication number: 20100089284Abstract: The invention provides a colorant compound represented by the following general formula (1): wherein R1 and R2 represent independently from each other a species selected from at least one of a hydrogen atom, an alkyl group, and an aralkyl group. R3 represents a species selected from at least one of a hydrogen atom, a cyano group, and —COR5, where R5 is any of a hydroxyl group, an alkoxy group, and an amino group. R4 represents a species selected from at least one of a hydrogen atom, an alkyl group, an aryl group, and an aralkyl group. Cy represents an aryl group. Optionally, at least one anionic group may be present in the general formula (1).Type: ApplicationFiled: October 12, 2009Publication date: April 15, 2010Applicant: CANON KABUSHIKI KAISHAInventors: Masatake Tanaka, Masashi Kawamura, Yasuaki Murai, Masashi Hirose, Takeshi Miyazaki
-
Patent number: 7687500Abstract: Oxetane-containing nucleosides, particularly non-reducing psiconucleoside oxetanes are described herein. Therapeutic application of these oxetane compounds toward the treatment of nucleoside analog related disorders such as disorders involving cellular proliferation and infection are also described.Type: GrantFiled: January 24, 2008Date of Patent: March 30, 2010Assignee: The University of ConnecticutInventors: Amy R. Howell, Rosa C. Taboada, Stewart K. Richardson
-
Publication number: 20100076199Abstract: The present invention relates to methods for the preparation of pyridone carboxylic acids for use as intermediates in the preparation of various synthetic organic compounds. The pyridone carboxylic acids can for example be used as intermediates in the production of potent antitumor agents, antifungal agents, antiviral agents, psychotherapeutic agents or contrast imaging agents for MRI.Type: ApplicationFiled: September 17, 2009Publication date: March 25, 2010Applicant: GE HEALTHCARE ASInventors: VIJAYA RAJ KUNIYIL KULANGARA, TILAK T. RAJ
-
Publication number: 20100069440Abstract: Disclosed are compounds of the formula I: wherein R1, R2, V, W, X, Y and Z can be as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors.Type: ApplicationFiled: October 14, 2009Publication date: March 18, 2010Inventors: Bob M. Moore, II, Steven Gurley, Suni Mustafa
-
Patent number: 7678792Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFR?, PDGFR?, CSF1R, Abl, BCR-Abl, CSK, JNK1, JNK2, p38, p70S6K, TGF?, SRC, EGFR, trkB, FGFR3, FLT3, Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2?, BRK, KDR, c-raf or b-raf kinase, or mutant forms thereof.Type: GrantFiled: October 16, 2007Date of Patent: March 16, 2010Assignee: IRM LLCInventors: Donatella Chianelli, Christopher Cow, Yun He, Songchun Jiang, Xiaolin Li, Xiaodong Liu, Zuosheng Liu, Jon Loren, Valentina Molteni, Juliet Nabakka, Pingda Ren, Taebo Sim, Xiaodong Wang, Shuli You
-
Publication number: 20100056787Abstract: The present invention relates to chelating agents, in particular to chelating agents which are capable of forming complexes with paramagnetic metal ions such as iron (III) and gadolinium (III). The invention also relates to the complexes formed and their use as MRI contrast agents.Type: ApplicationFiled: January 11, 2008Publication date: March 4, 2010Applicant: GE Healthcare ASInventors: Harry John Wadsworth, Ian Martin Newington, Clare L. Jones, Amanda Ewan, Dennis O'Sheo
-
Publication number: 20100022779Abstract: The invention relates to compounds of formula 1 and formula 10 and to compositions comprising these compounds and methods of treating gastrointestinal disorders by administering these compounds.Type: ApplicationFiled: July 21, 2009Publication date: January 28, 2010Applicant: NYCOMED GMBHInventors: Bernhard Kohl, Bernd Müller, Dieter Haag, Wolfgang-Alexander Simon, Karl Zech, Michael David, Oliver Von Richter, Felix Huth
-
Patent number: 7652144Abstract: A compound of formula XIX wherein R1, R2, Z1, Z2, Q1, Q2 and Q3 as defined in the specification.Type: GrantFiled: June 18, 2007Date of Patent: January 26, 2010Assignee: Aventis Pharma LimitedInventors: Garry Fenton, Tahir Nadeem Majid, Malcolm Norman Palfreyman
-
Patent number: 7638514Abstract: There are described compounds of formula (I) wherein X1 and X2 are each independently of the other fluorine, chlorine or bromine; A1 and A2 are, for example, a bond or a C1-C6alkylene bridge; A3 is a C1-C6alkylene bridge; R1 and R2 are, for example, halogen, OH, SH, CN, nitro, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkyl-carbonyl, C2-C6alkenyl, C2-C6haloalkenyl or C3-C6alkynyl; R,3 is, for example, H, halogen, OH, SH, CN, nitro, C1-C6alkyl or C1-C6haloalkyl; R4 and R5 are, for example, H, halogen, cyano, nitro, C1-C6alkyl or C1-C3haloalkyl; m is 1 or 2; Y is, for example, O, S, SO or SO2; Q is, for example, O, S, SO or SO2; W is, for example, a bond, O, S, SO, S02, —C(?O)—O— or —O—C(?O)—; T is, for example, a bond, O, S, SO, SO2, —C(?O)—O— or —O—C(?O)—; and E is aryl unsubstituted or substituted from one to five times or heterocyclyl unsubstituted or, depending upon the possibilities of substitution on the ring, substituted from one to four times; and, where applicable, their possible E/Z isomers, E/Z isomeric mixtType: GrantFiled: August 25, 2004Date of Patent: December 29, 2009Assignee: Syngenta Crop Protection, Inc.Inventors: Werner Zambach, Stephan Trah, Roger Graham Hall, William Lutz
-
Patent number: 7629363Abstract: Disclosed are compounds Formula I and pharmaceutically acceptable salts thereof, wherein R1, R2, R3/R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.Type: GrantFiled: September 14, 2005Date of Patent: December 8, 2009Assignee: Pfizer IncInventors: Balekudru Devadas, John Walker, Shaun R. Selness, Terri L. Boehm, Richard C. Durley, Rajesh Devraj, Brian S. Hickory, Paul V. Rucker, Kevin D. Jerome, Heather M. Madsen, Edgardo Alvira, Michele A. Promo, Radhika M. Blevis-Bal, Laura D. Marruto, Jeff Hitchcock, Thomas Owen, Win Naing, Li Xing, Huey S. Shieh, Aruna Sambandam, Shuang Liu, Ian L. Scott, Kevin F. McGee
-
Patent number: 7629365Abstract: 3-Chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H)-pyridinone, having the following formula: is described along with its pharmaceutically acceptable salts, processes for its preparation, pharmaceutical formulations thereof and its uses in treatment of certain parasitic infections such as malaria.Type: GrantFiled: May 31, 2007Date of Patent: December 8, 2009Assignee: Glaxo Group LimitedInventors: Jose Maria Bueno Calderon, Jesus Chicharro Gonzalo, M Pilar Manzano Chinchon
-
Publication number: 20090298889Abstract: The present invention herein provides a 2-pyridone derivative which has a cell adhesion-inhibitory activity and which is useful for preventing and/or treating pathema or disease conditions including, for instance, inflammations which relate to leukocytic infiltration. The 2-pyridone derivative is a compound represented by the following general formula (1). In the formula, R1 represents, for instance, a phenyl or pyridyl group, R2 represents, for instance, a phenyl group, R3 represents, for instance, a lower alkyl group, R4 represents, for instance, a lower alkyl group, R5 represents, for instance, a lower alkyl group, and R6 represents, for instance, a lower alkyl group.Type: ApplicationFiled: June 30, 2006Publication date: December 3, 2009Applicant: SATO PHARMACEUTICAL CO., LTD.Inventors: Masatoshi Kato, Hiroyuki Kusakabe, Satoshi Yanagihara, Hidenori Akizawa, Yushi Tamoto
-
Publication number: 20090286818Abstract: wherein R1, R2, V, W, X, Y and Z can be as defined herein. The compounds can be used in the treatment of disorders mediated by the cannabinoid receptors.Type: ApplicationFiled: May 19, 2009Publication date: November 19, 2009Inventors: Bob M. Moore, II, Steven Gurley, Suni Mustafa
-
Patent number: 7598380Abstract: A method of preparing azaindole compounds for antiviral use having the formulaType: GrantFiled: July 25, 2006Date of Patent: October 6, 2009Assignee: Bristol-Myers Squibb CompanyInventors: Wansheng Liu, Sunil S. Patel, Nicolas Cuniere, Yvonne Lear, Prashant P. Deshpande, Jeffrey N. Simon, Chiajen Lai, Annie J. Pullockaran, Nachimuthu Soundararajan, Jeffrey T. Bien
-
Publication number: 20090247588Abstract: The present invention relates to compounds formula I: and pharmaceutically acceptable salts thereof, wherein R1 to R8 are as defined in the description and claims for use as HDL-cholesterol raising agents in the treatment and/or prophylaxis of diseases or disorders that can be treated with such agents such as dyslipidemia.Type: ApplicationFiled: March 16, 2009Publication date: October 1, 2009Inventors: Paul Hebeisen, Constantinos G. Panousis, Stephan Roever, Pius Waldmeier, Matthew Wright
-
Patent number: 7585883Abstract: The present invention is directed to substituted pyridines, methods for their preparation and methods for their use in the treatment and/or prevention of mast cell related conditions.Type: GrantFiled: October 31, 2005Date of Patent: September 8, 2009Assignee: Rigel Pharmaceuticals, Inc.Inventors: Ankush Argade, David Carroll, Alexander B. Rossi
-
Publication number: 20090220622Abstract: The present invention relates to the use of mimosine or a derivative thereof for treating the cutaneous effects of psoriasis and related skin disorders.Type: ApplicationFiled: January 23, 2007Publication date: September 3, 2009Applicant: XL GLOBAL CORPORATIONInventors: Moises Gabriel Zeitune, Rubén Martin Laguens
-
Patent number: 7576203Abstract: The present invention provides an industrially useful method for synthesizing a cyclic diamine derivative (4) or a salt thereof which serves as an ACAT inhibitor. A 2-hydroxyacetylaminopyridine compound represented by formula (1), and a method for producing a cyclic diamine derivative represented by formula (4) or a salt thereof from compound (1) through 1) Step A-1, 2) Steps B-1 and B-2, or 3) Steps B-1, B-3, and B-4.Type: GrantFiled: June 30, 2005Date of Patent: August 18, 2009Assignee: Kowa Co., Ltd.Inventors: Kimiyuki Shibuya, Ayako Tosaka
-
Patent number: 7563893Abstract: The present invention relates to a 3-phenyl-cinnoline compound or a physiologically acceptable salt thereof, and a cell proliferation inhibitor and an antitumor agent comprising the same, as an active ingredient.Type: GrantFiled: December 10, 2003Date of Patent: July 21, 2009Assignee: Nippon Kayaku Kabushiki KaishaInventors: Shunsuke Kuroiwa, Junko Odanaka, Sakiko Maruyama, Yoshitaka Sato, Arihiro Tomura, Hiroshi Sato, Yoshikazu Suzuki